SPEEDX
11.2.2020 14:02:38 CET | Business Wire | Press release
SpeeDx Pty Ltd, the developer of innovative clinical diagnostics to support improved patient outcomes, today announced it has raised $15 million in additional series B equity investment from U.S.-based Northpond Ventures. This investment comes with a company value uptick of 21.22%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005496/en/
"SpeeDx's molecular diagnostic solutions are having a profound global impact in the areas of STIs, antibiotic resistance markers, and respiratory diseases," said Michael P. Rubin, M.D., Ph.D., Founder and CEO of Northpond Ventures. "We've already seen how their diagnostic solutions for infectious diseases can translate to improved patient management, and Northpond Ventures is thrilled to continue this partnership as SpeeDx grows their global footprint."
In the U.S., SpeeDx is finalizing clinical trials for their flagship product Resistance Plus MG, detecting the STI Mycoplasma genitalium (Mgen) and genetic markers linked to antibiotic resistance of the common macrolide frontline treatment. Resistance rates in Mgen infection are steadily rising around the world, leading to difficult-to-treat infections.1-3 Recommendations for resistance testing to better inform treatment decisions can be found in Mgen management guidelines around the world.4-9 A recent partnership with Cepheid also saw the development of Resistance Plus MG on the GeneXpert® platform (available in Australia, New Zealand, and parts of Europe), as part of their FleXible cartridge program, this product was launched late 2019 and is providing clinicians with timely information to assist management of Mgen infections and adhere to management guidelines.
SpeeDx CFO Bhavin Raval said, "As we rapidly expand and enter into more collaborative partnerships, these additional funds will support the necessary structural and process investments to ensure strong pipeline and service growth throughout this year and beyond."
Pre-clinical testing is wrapping up in preparation for commencing U.S.-based clinical trials for Resistance Plus® GC—a test to determine susceptibility of gonorrhoea infections to ciprofloxacin treatment. This test has been granted Breakthrough Device designation by the FDA which will fast track the registration process. This will provide doctors and patients the option of using ciprofloxacin instead of ceftriaxone, one of the last remaining antibiotics available for multi-drug resistant gonorrhoea infections.
About SpeeDx
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com
About Northpond Ventures
Northpond Ventures is a leading global science-driven innovation firm dedicated to building and empowering breakthrough companies in life sciences and technology. Since its founding, Northpond Ventures has risen to become among the most-active investors in the life sciences and molecular diagnostics industries and is very active in all disciplines related to healthcare and affiliated industries. Its investments target the greatest scientists, innovators and entrepreneurs in life sciences, diagnostics, AI and machine learning, therapeutics, and affiliated sectors. Northpond has in excess of $500 million of committed capital, with over 20 businesses represented in its portfolio. For more information, please visit: npv.vc .
References
- Read T R H, Fairley C K, Murray G L, et al . Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation, Clinical Infectious Diseases, ciy477, https://doi.org/10.1093/cid/ciy477
- Getman D, Jiang A, O'Donnell M, Cohen S. 2016. Mycoplasma genitalium prevalence, coinfection, and macrolide antibiotic resistance frequency in a multicenter clinical study cohort in the United States. J Clin Microbiol 54:2278-2283.
- Murray GL, Bradshaw CS, Bissessor M, et al. Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium. Emerging Infectious Diseases. 2017;23(5):809-812. doi:10.3201/eid2305.161745.
- Jensen et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1650-1656.
- Horner PJ et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016 Oct;27(11):928-37.
- 2018 BASHH UK national guideline for the management of infection with Mycoplasma genitalium. Available online at: https://www.bashhguidelines.org/media/1198/mg-2018.pdf
- Groupe Infectiologie Dermatologique et Infections Sexuellement GRIDIST and Société Fançaise de Dermatologie – Press Release. Available online at: https://www.sfdermato.org/actualites/communique-commun-gridist-et-sfd.html
- Australian STI Management Guidelines – Mycoplasma genitalium 2018. http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
- https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections/canadian-guidelines-sexually-transmitted-infections-49.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005496/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paris Outpaces London as Europe’s Top AI City, According to The Observer’s AI Cities Index20.10.2026 13:11:00 CEST | Press release
Paris has claimed Europe’s AI crown, ranking higher than London as the continent’s leading hub of AI excellence. Yet Europe is struggling to compete with cities across the US and Asia, whose AI hubs lead the global rankings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020799504/en/ The Observer AI Cities Index Top Ten Cities 2026 This is according to The Observer’s inaugural AI Cities Index: a first-of-its-kind report identifying which cities are leading the global AI race when it comes to originating, building, financing and integratingartificial intelligence (AI). The new ranking has scored 57 cities across 36 countries based on levels of AI investment (assessing public, private and procedural investments in AI), innovation (capturing breakthroughs in technology that are indicative of greater capacity for AI in the future) and implementation (the availability of the infrastructure, institutions and systems needed to
New Research from One Biosciences Shows Single-Cell Profiling Can Identify Which Ovarian Cancer Tumors are Predisposed to Chemotherapy Resistance20.10.2026 13:02:00 CEST | Press release
Researchers from French National Centre for Scientific Research (CNRS), Institut Curie, Sorbonne Université and One Biosciences show ovarian cancer tumor cells may be epigenetically primed to resist chemotherapyClinical single-cell profiling at diagnosis may enable more personalized treatment strategies in difficult-to-treat cancer One Biosciences today announced data showing some ovarian cancer tumor cells are predisposed to resist chemotherapy and single-cell profiling at diagnosis can identify tumor profiles that indicate which patients are likely to experience treatment failure, ultimately enabling more personalized treatment strategies. Researchers from One Biosciences, French National Centre for Scientific Research (CNRS), Institut Curie, and Sorbonne Université found that the cellular changes linked to the development of resistance to cytotoxic chemotherapy cannot be explained by DNA mutations alone: the functional and epigenetic state of tumor cells play a key role and initial
IDWS 2026 Brings the World Together to Accelerate the Deployment of Water Solutions20.10.2026 12:38:00 CEST | Press release
Jeddah is preparing to host the fifth edition of the Innovation Driven Water Sustainability Conference (IDWS 2026) from 14 to 16 December 2026. The conference aims to accelerate the transition of water solutions from research and development to real-world deployment, while connecting innovators with investors and end users to strengthen water security, improve service efficiency, and enhance the sustainability of water resources worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020192877/en/ Main session from IDWS 2025 (Photo: AETOSWire) The conference will bring together experts, researchers, innovators, investors, and representatives of water-sector organisations from more than 140 countries. It will feature over 250 speakers and is expected to attract more than 10,000 participants, alongside an international exhibition showcasing more than 150 global brands. Eng. Tariq Al-Ghafari, Deputy president for innovatio
European Wealth Firms Build Private Markets Capability Faster Than They Communicate It, Peregrine Report Finds20.10.2026 10:15:00 CEST | Press release
Capability outpaces communication: 73% of the 30 firms show visible private markets engagement, yet only 40% have a dedicated landing page explaining it to clients Swiss private banks set the benchmark: 70% maintain dedicated private markets destinations, led by Julius Baer, UBP, Pictet and Lombard Odier Visibility is concentrated: five firms generate half of all wealth management media coverage, and alternatives just 7% Europe's leading wealth managers have built genuine private markets capability but most have yet to explain it to the clients they built it for, according to The Wealth 30, a new report from Peregrine Communications. The study analyses how 30 leading UK and European wealth managers and private banks position private markets. It concludes that communication, not product, is now the biggest barrier to differentiation in the wealth channel. Capability outpaces explanation 73% of the Wealth 30 engage in private markets yet only 40% operate a dedicated landing page explaini
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia’s Automotive Sector20.10.2026 10:00:00 CEST | Press release
Global AI-first cloud communications platform Infobip strengthens its collaboration with Yamaha Indonesia Motor Manufacturing (YIMM) to transform customer engagement through WhatsApp-powered conversational experiences designed to drive stronger personalization and faster customer interactions. As Indonesia’s consumers increasingly adopt digital-first purchasing behaviors, Yamaha Indonesia is evolving how it connects with customers across the buying journey. Today’s motorcycle buyers often research products through Yamaha’s social media, websites, and video reviews on YouTube before visiting dealerships, raising expectations for brands to deliver fast, seamless, and highly personalized communication. For more than two years, Infobip has supported Yamaha Indonesia in building connected customer engagement strategies that integrate WhatsApp across the company’s wider digital ecosystem, including its websites, social media platforms, and customer touchpoints. The collaboration reflects the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom